Comments
Dr. Reddy’s Laboratories Ltd has launched its authorised generic version of Par Pharmaceutical’s Vasostrict (vasopressin injection) vials in the US market with approval from the US Food and Drug Administration (USFDA).
“We are pleased to provide this important authorised generic product to patients, especially in these difficult times of Covid-19,” said Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories Inc, in a release issued on Wednesday.
The Vasostrict brand market had US sales of approximately $878.5 million for the most recent 12 months ending in December 2021 according to IQVIA Health, the Hyderabad-based company said.
The injection is generally indicated in the treatment of diabetes insipidus.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.